Therapeutic effects of surgical debulking of metastatic lymph nodes in cervical cancer IIICr: a trial protocol for a phase III, multicenter, randomized controlled study (KGOG1047/DEBULK trial)
This study will include patients with a short-axis diameter of a pelvic or para-aortic LN ≥2 cm or ≥3 LNs with a short-axis diameter ≥1 cm and for whom CCRT is planned. The treatment arms will be randomly allocated in a 1:1 ratio to either receive CCRT (control arm) or undergo surgical debulking of bulky or multiple LNs before CCRT (experimental arm). CCRT consists of extended-field external beam radiotherapy/pelvic radiotherapy, brachytherapy and LN boost, and weekly chemotherapy with cisplatin (40 mg/m²), 4-6 times administered intravenously. The primary endpoint will be 3-year progression-free survival rate. The secondary endpoints will be 3-year overall survival rate, treatment-related complications, and accuracy of radiological diagnosis of bulky or multiple LNs.TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05421650; Clinical Research Information Service Identifier: KCT0007137.PMID:38330380 | DOI:10.3802/jgo.2024.35.e57
Source: Journal of Gynecologic Oncology - Category: OBGYN Authors: Bo Seong Yun Kwang-Beom Lee Keun Ho Lee Ha Kyun Chang Joo-Young Kim Myong Cheol Lim Chel Hun Choi Hanbyoul Cho Dae-Yeon Kim Yun Hwan Kim Joong Sub Choi Chae Hyeong Lee Jae-Weon Kim Sang Wun Kim Yong Bae Kim Chi-Heum Cho Dae Gy Hong Yong Jung Song Seob Jeo Source Type: research
More News: Brachytherapy | Cancer | Cancer & Oncology | Cervical Cancer | Chemotherapy | Clinical Trials | External Beam Therapy | OBGYN | Study